Linked Life Data

12841924

Source:http://linkedlifedata.com/resource/pubmed/id/12841924

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-7-4
pubmed:abstractText
Objective and setting: Azelastine (AZE) in a novel, eye drop, formulation, was compared with topically applied sodium cromoglycate (SCG) and placebo (PLA) in the treatment of seasonal allergic conjunctivitis or rhino-conjunctivitis in a multicentre, parallel group study. Research design: 144 subjects ranging in age from 16 to 65 years participated. All had at least a 2-year history of seasonal allergic conjunctivitis and were symptomatic at the time of inclusion. Medications were administered topically either twice daily (AZE/PLA) or four times daily (SCG) over a 2-week treatment period. Method and outcome measures: Azelastine and placebo were compared double-blind; the comparison versus SCG was carried out in an open manner. Itching, redness, flow of tears, eyelid swelling, foreign-body sensation, photophobia, soreness and discharge were scored on a 4-point severity scale. RESULTS: Results for the decrease of main conjunctivitis symptoms (itching, tearing and conjunctival redness) showed a marked effect for both active treatments on day 3 with a sustained improvement on days 7 and 14. A clear response to treatment (an improvement of sum scores for day 3 of >/=3 points compared to baseline) occurred in 85.4% of azelastine-treated patients, 83.0% of sodium cromoglycate patients and 56.3% of placebo patients. Response rates for both active treatments were statistically superior to those for placebo (azelastine p = 0.005; sodium cromoglycate p = 0.007). Global assessment of efficacy was at least 'satisfactory' for 90.0% of azelastine patients, 81.3% of sodium cromoglycate patients and 66.3% of placebo-treated patients. The most frequent adverse effects were transient application site reactions which tended to disappear with increasing duration of treatment, and, less frequently, taste perversion. CONCLUSION: The results of this study indicate that the therapeutic use of azelastine eye drops in patients with seasonal allergic conjunctivitis or rhino-conjunctivitis can be recommended.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-7995
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
313-20
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12841924-Administration, Topical, pubmed-meshheading:12841924-Adolescent, pubmed-meshheading:12841924-Adult, pubmed-meshheading:12841924-Aged, pubmed-meshheading:12841924-Anti-Allergic Agents, pubmed-meshheading:12841924-Anti-Asthmatic Agents, pubmed-meshheading:12841924-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:12841924-Conjunctivitis, Allergic, pubmed-meshheading:12841924-Cromolyn Sodium, pubmed-meshheading:12841924-Double-Blind Method, pubmed-meshheading:12841924-Female, pubmed-meshheading:12841924-Histamine H1 Antagonists, pubmed-meshheading:12841924-Humans, pubmed-meshheading:12841924-Male, pubmed-meshheading:12841924-Middle Aged, pubmed-meshheading:12841924-Ophthalmic Solutions, pubmed-meshheading:12841924-Phthalazines, pubmed-meshheading:12841924-Rhinitis, Allergic, Seasonal
pubmed:year
2003
pubmed:articleTitle
Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis.
pubmed:affiliation
Southbank Surgery, Glasgow, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study